Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple sclerosis: free light chains in cerebrospinal fluid.

R A Rudick, D R Peter, J M Bidlack

    Neurology
    |October 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Multiple Sclerosis Performance Test: validation of self-administered neuroperformance modules.

    European journal of neurology·2020
    Same author

    Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: A retrospective analysis.

    Multiple sclerosis (Houndmills, Basingstoke, England)·2015
    Same author

    Simple MRI metrics contribute to optimal care of the patient with multiple sclerosis.

    AJNR. American journal of neuroradiology·2014
    Same author

    Prescribing recommendations for interferon-Beta in multiple sclerosis.

    CNS drugs·2013
    Same author

    Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis.

    Neurology·2011
    Same author

    Change in quality of life in patients with relapsing-remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon {beta}-1a.

    Multiple sclerosis (Houndmills, Basingstoke, England)·2011
    Same journal

    Phenotype, Severity, and Therapy of Patients With LRP4 Antibody-Associated Myasthenia Gravis in the German Myasthenia Gravis Registry.

    Neurology·2026
    Same journal

    Association of Changes in Intrinsic Capacity With Cognitive Decline and Dementia: A Prospective Cohort Study.

    Neurology·2026
    Same journal

    Role of the Upper Motor Neuron in the Generation of Fasciculations in Early Disease Stages of Amyotrophic Lateral Sclerosis.

    Neurology·2026
    Same journal

    Factors Associated With Disability Improvement and Worsening Independent of Attacks in Patients With AQP4-IgG+ NMOSD and MOGAD: A Multicenter Cohort Study.

    Neurology·2026
    Same journal

    Cost-Effectiveness of Intracranial Aneurysm Screening: A Systematic Review.

    Neurology·2026
    Same journal

    Rare Eating Epilepsy: Co-Occurrence of Focal Cortical Dysplasia and Gray Matter Heterotopia.

    Neurology·2026
    See all related articles

    Free light chains were detected in cerebrospinal fluid (CSF) of multiple sclerosis (MS) patients, but not in controls. These findings suggest an intrathecal origin, potentially from plasma cells, rather than IgG degradation.

    Area of Science:

    • Neurology
    • Immunology
    • Biochemistry

    Background:

    • Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system.
    • The role of immunoglobulin free light chains (FLCs) in the pathogenesis of MS is not fully understood.
    • Previous studies have focused on FLCs in serum, with limited investigation in cerebrospinal fluid (CSF).

    Purpose of the Study:

    • To investigate the presence and origin of free light chains (FLCs) in the cerebrospinal fluid (CSF) of patients with multiple sclerosis (MS).
    • To differentiate between intrathecal production and systemic origin of FLCs in MS.
    • To explore the potential source of FLCs in MS CSF, distinguishing between de novo synthesis and IgG degradation.

    Main Methods:

    • Analysis of cerebrospinal fluid (CSF) and matched serum samples from 18 MS patients and 14 patients with other neurologic diseases.

    Related Experiment Videos

  • Detection of kappa and lambda free light chains (monomers and dimers) and intact immunoglobulin G (IgG).
  • Incubation of control IgG with MS CSF to assess potential FLC release from intact IgG.

    • Main Results:

    • Free light chains (FLCs) were detected in the CSF of 18 MS patients, but not in any control patients.
    • Kappa and lambda FLC dimers were common in MS CSF, with monomers less frequent; free heavy chains were absent.
    • FLCs were not detected in matched serum samples, and MS CSF did not induce FLC release from control IgG.

    Conclusions:

    • The presence of FLCs in MS CSF suggests an intrathecal origin.
    • Findings indicate that FLCs in MS CSF are likely produced by local plasma cells, not derived from systemic circulation or IgG degradation.
    • This study highlights the potential diagnostic and pathogenetic significance of intrathecal FLCs in multiple sclerosis.